FDA-Approved Indications for Proton Pump Inhibitors in Adults PPIs are used to prevent and treat gastric acid-related conditions. The FDA-approved indications for use include: Healing of erosive esophagitis (EE); Maintenance of healed EE;
ICD-9-CM V58.69 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, V58.69 should only be used for claims with a date of service on or before September 30, 2015. For claims with a date of service on or after October 1, 2015, use an equivalent ICD-10-CM code (or codes).
For claims with a date of service on or after October 1, 2015, use an equivalent ICD-10-CM code (or codes). 2015/16 ICD-10-CM Z79.899 Other long term (current) drug therapy
2016 2017 2018 2019 Billable/Specific Code POA Exempt. Z79.811 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2018/2019 edition of ICD-10-CM Z79.811 became effective on October 1, 2018.
83.
The ICD-10 section that covers long-term drug therapy is Z79, with many subsections and specific diagnosis codes.
The patient's primary diagnostic code is the most important. Assuming the patient's primary diagnostic code is Z76. 89, look in the list below to see which MDC's "Assignment of Diagnosis Codes" is first.
V58. 69 - Long-term (current) use of other medications. ICD-10-CM.
Long-term medicine Any medicine you have to take for three or more months to control symptoms or to prevent complications from a condition. Examples of conditions that might require long-term medicine include: high blood pressure, high cholesterol, diabetes, arthritis, heart conditions, and long-term pain.
ICD-10 code Z79. 891 for Long term (current) use of opiate analgesic is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
ICD-10 code Z76. 89 for Persons encountering health services in other specified circumstances is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
Codes from category Z15 should not be used as principal or first-listed codes.
Z codes may be used as either a first-listed (principal diagnosis code in the inpatient setting) or secondary code, depending on the circumstances of the encounter. Certain Z codes may only be used as first-listed or principal diagnosis.
ICD-10-CM Diagnosis Code Z79 Z79.
There have been case reports that have associated PPI use with the development of AIN.4,11 This is a humoral- and cell-mediated hypersensitivity re...
Drug-induced lupus erythematosus (DILE) is a lupus-like syndrome that usually resolves after discontinuation of the medication.21 Drug-induced suba...
Currently, there are six PPIs available: dexlansoprazole (Dexilant), esomeprazole (Nexium), lansoprazole (Prevacid), omeprazole (Prilosec), pantopr...
You should be sure to read the label or product packaging and follow the directions for use. However, generally speaking, these products are taken...
PPIs are generally well tolerated. The most common side effects reported include headache, diarrhea, nausea, and vomiting. Reports of more serious...
PPIs may make some medications less effective by reducing their absorption from the stomach. Be certain to read the product packaging carefully and...
OTC products should not be used for more than 2 weeks unless you are told to do so by your healthcare provider. You should not abruptly discontinue...
Through effective counseling and provision of medication therapy management sessions , pharmacists can ensure that PPI use is associated with appropriate indications utilizing the lowest effective dose for the shortest duration possible.
Several significant drug interactions are associated with PPIs due to their ability to dramatically reduce gastric acid production and raise gastric pH. Medications that require an acidic environment for absorption may have reduced oral bioavailability in patients treated with PPIs. Some examples of agents that may be affected and have reduced efficacy include, but are not limited to, itraconazole, ketoconazole, isoniazid, oral iron supplements, and several protease inhibitors. If alternative therapies cannot be used, patients receiving these medications should be counseled to take them towards the end of the PPI dosing interval and be monitored for appropriate responses to therapy. 25
Since the introduction of the first proton pump inhibitor (PPI) in 1989, this class of medications has become a staple in the management of gastroesophageal reflux disease (GERD) and other acid-related disorders. PPIs are potent agents that significantly reduce acid secretion by irreversibly binding to H + /K + adenosine triphosphatase, ...
PPI use has been associated with an increased risk of developing community-acquired pneumonia (CAP). Acid suppression leads to an increase in gastric pH, allowing for the overgrowth of non- Helicobacter pylori bacteria in gastric juices, gastric mucosa, and the duodenum. 2 This can potentially lead to microaspiration and lung colonization.
Hypomagnesemia. Although rare, hypomagnesemia is associated with PPI use and can be life-threatening. Symptoms include muscle weakness and cramps, tetany, convulsions, arrhythmias, and hypotension.
Long term (current) drug therapy Z79- 1 drug abuse and dependence (#N#ICD-10-CM Diagnosis Code F11#N#Opioid related disorders#N#2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code#N#F11 -#N#ICD-10-CM Diagnosis Code F19#N#Other psychoactive substance related disorders#N#2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code#N#Includes#N#polysubstance drug use (indiscriminate drug use)#N#F19) 2 drug use complicating pregnancy, childbirth, and the puerperium (#N#ICD-10-CM Diagnosis Code O99.32#N#Drug use complicating pregnancy, childbirth, and the puerperium#N#2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code#N#Use Additional#N#code (s) from F11 - F16 and F18 - F19 to identify manifestations of the drug use#N#O99.32-)
Z79.02 Long term (current) use of antithrombotics/antiplatelets. Z79.1 Long term (current) use of non-steroidal anti-inflammatories (NSAID) Z79.2 Long term (current) use of antibiotics. Z79.3 Long term (current) use of hormonal contraceptives. Z79.4 Long term (current) use of insulin.
A type 2 excludes note indicates that the condition excluded is not part of the condition it is excluded from but a patient may have both conditions at the same time. When a type 2 excludes note appears under a code it is acceptable to use both the code ( Z79) and the excluded code together. drug abuse and dependence (.
Z79.811 is a valid billable ICD-10 diagnosis code for Long term (current) use of aromatase inhibitors . It is found in the 2021 version of the ICD-10 Clinical Modification (CM) and can be used in all HIPAA-covered transactions from Oct 01, 2020 - Sep 30, 2021 .
Z79.811 also applies to the following: Inclusion term (s): Long term (current) use of anastrozole (Arimidex) Long term (current) use of exemestane (Aromasin) Long term (current) use of letrozole (Femara) MS-DRG - Medicare Severity-Diagnosis Related Group.
DO NOT include the decimal point when electronically filing claims as it may be rejected. Some clearinghouses may remove it for you but to avoid having a rejected claim due to an invalid ICD-10 code, do not include the decimal point when submitting claims electronically. See also:
The FDA requires that PPI labeling include safety information about a possible increased risk of fractures of the hip, wrist, and spine. This requirement is based on an FDA review of several epidemiological studies with findings indicating that patients who may bear the highest risk for these fractures received a high dose of a PPI or had a duration of PPI therapy lasting longer than 1 year. The majority of these studies included individuals 50 years or older.[14] The FDA requires that a Medication Guide be dispensed with every new or refilled PPI prescription. The Medication Guide informs patients and providers about the risk of bone fractures that may occur when taking a PPI. Links to the Medication Guides can be found at http://www.fda.gov/Drugs/
In March 2011, the FDA published a Drug Safety Communication to inform consumers and health professionals that long-term use of PPIs can cause hypomagnesemia . In 25 percent of patients, magnesium supplementation was not sufficient to correct PPI-induced hypomagnesemia; rather, PPI therapy had to be discontinued. The deficiency did not appear to be dose-related and reappeared after rechallenge with a PPI. The FDA recommends obtaining a serum magnesium level prior to initiation of therapy if a patient is to be on prolonged treatment.[15]
Symptoms of CDAD include abdominal pain, fever, and watery stools. Patients who take a PPI and develop diarrhea that does not improve should be evaluated for CDAD. Patients with advanced age, certain chronic medical conditions, and patients taking broad spectrum antibiotics are at greatest risk for developing CDAD. The FDA recommends using the lowest dose and shortest duration of PPI therapy possible and recommends advising patients to seek medical attention if they develop symptoms of CDAD.[16] The previously mentioned Medication Guide also informs patients and providers about the risk of CDAD when taking a PPI.